Oleic acid NEW
Price | $30 |
Package | 500mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-01 |
Product Details
Product Name: Oleic acid | CAS No.: 112-80-1 |
Purity: 99.91% | Supply Ability: 10g |
Release date: 2024/11/01 |
Product Introduction
Bioactivity
名稱 | Oleic acid |
描述 | Oleic acid (Glycon Wo) is a natural product, a common monounsaturated fatty acid found in a variety of animal and vegetable fats and oils. Palmitic acid is a Na+/K+ ATPase activator. |
體外活性 | METHODS: Human tumor cells HCG-27, AGS, MDA-MB-231, SGC7901, BGC823 and MCF-7 were treated with Oleic acid (400 μM) for 24-72 h. Cell viability was detected using MTT. RESULTS: Oleic acid stimulated cell viability in HGC-27, MDA-MB-231 cells, and inhibited cell viability in AGS, SGC7901, BGC823 and MCF-7 cells. [1] METHODS: Renal cell carcinoma cells 786-O were treated with Oleic acid (0.05-0.2 mM/L) for 48 h. Apoptosis was detected by Flow Cytometry. RESULTS: Oleic acid retarded apoptosis of 786-O cells in a concentration-dependent manner. [2] |
體內(nèi)活性 | METHODS: To detect the antitumor activity in vivo, Oleic acid (10 mg/kg) was administered by gavage to LKB1fl/flp53fl/fl endometrial tumor mouse model five days per week for four weeks. RESULTS: Oleic acid treatment for four weeks significantly inhibited tumor growth by 52.1%.Oleic acid exhibits anti-tumor activity in endometrial cancers, which is dependent on the PTEN/AKT/mTOR signaling pathway. [3] METHODS: To study its role in ischemic injury, Oleic acid (10-30 mg/kg, 5% Tween 20 in sterile saline) was administered intraperitoneally to rodent models of middle cerebral artery occlusion (MCAO), photochromic and four-vessel occlusion (4-VO). RESULTS: Oleic acid administration reduced MCAO-induced infarct volume and functional deficits, photochromic-induced infarct volume, and 4-VO-induced hippocampal neuronal death. [4] |
存儲條件 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 60 mg/mL (212.42 mM) 5% DMSO+95% Saline : 3 mg/mL (10.62 mM), Working solution is recommended to be prepared and used immediately. |
關(guān)鍵字 | Inhibitor | Oleic acid | Endogenous Metabolite | Sodium potassium pump | inhibit | Na+/K+ ATPase | Apoptosis |
相關(guān)庫 | 經(jīng)典已知活性庫 | 中藥單體化合物庫 | 風(fēng)味化合物庫 | 藥物功能重定位化合物庫 | 天然產(chǎn)物庫 | 高通量篩選天然產(chǎn)物庫 | 化妝品成分化合物庫 | 腸道微生物代謝化合物庫 | 古代經(jīng)典名方目錄分子庫 | 抗癌藥物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/200KG |
VIP3Y
|
Hebei Weibang Biotechnology Co., Ltd
|
2024-10-31 | |
$100.00/25KG |
VIP6Y
|
Hebei Weibang Biotechnology Co., Ltd
|
2024-10-28 | |
$0.00/1KG |
VIP4Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-20 | |
$3.50/1kg |
VIP1Y
|
Hebei Andu Technology Com.,Ltd
|
2024-08-16 | |
$100.00/50kg |
VIP1Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2024-08-09 | |
$6.00/1kg |
VIP1Y
|
HebeiShuoshengImportandExportco.,Ltd
|
2024-08-01 | |
$0.00/25kg |
VIP1Y
|
Hebei Mojin Biotechnology Co.,Ltd
|
2024-07-30 | |
$0.00/1KG |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2024-07-03 | |
$0.00/1Kg/Bag |
VIP4Y
|
Sinoway Industrial co., ltd.
|
2024-06-27 | |
$0.00/1kg |
VIP2Y
|
Hebei Kingfiner Technology Development Co.Ltd
|
2024-06-20 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY